Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
Investment firm Deerfield Management is the latest to find a gem in China, which has been rising as a source of biotech innovation over the past few years.
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard Read More »
